Asston Pharma

APL

Q: Is the debt of Asston Pharma increasing or decreasing?

The net debt of Asston Pharma is decreasing.Latest net debt of Asston Pharma is ₹3.81 Crs as of Sep-25.This is less than Mar-25 when it was ₹6.86 Crs.

Q: Is Asston Pharma stock expensive?

Asston Pharma is not expensive.Latest PE of Asston Pharma is 13.42, while 3 year average PE is 18.13. Also latest EV/EBITDA of Asston Pharma is 14.47 while 3yr average is 17.48.

Price

Nano Cap

₹60 Cr.

New to Zerodha? Sign-up for free.

Asston Pharmaceuticals manufactures and exports pharmaceutical formulations and nutraceutical products in domestic and African markets under the brand 'Asston'. Their product range includes Tablets, … More

Asston Pharmaceuticals manufactures and exports pharmaceutical formulations and nutraceutical produ… More

Low

68.00

52W Range

High

126

13.78

Sector PE

25.87

P/B

5.6

Div.Yield

ROE

40.35%

EBIDTA

14.92

ROCE

50.71

EPS

New to Zerodha? Sign-up for free.

Get instant stock alerts

Share Price
Financials
Revenue mix
Shareholdings
Peers
Forensics

Coming soon

Summary
Profit & Loss
Balance sheet
Cashflow

Yearly | Quarterly

View Detailed Summary

This data is currently unavailable for this company.

Yearly | Quarterly

(In Cr.)

(In Cr.)
This data is currently unavailable for this company.

Financial Ratio's

(In %)

Detailed P&L Report

(In Cr.)

Detailed Balance Sheet

Financial Year (In Cr.)

Detailed Cash Flow

Product wise
Location wise

APL
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

APL
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

More Info

Shareholdings

Holders

Detailed Shareholdings

This data is currently unavailable for this company.

Peers

Detailed Peers

Forensics

View Detailed Forensics

Recent events

News
Corporate Actions

Asston Pharmaceuticals' Unit 2 Commences Commercial Production

Jan 21, 2026

Asston Pharmaceuticals Receives Purchase Order

Sep 02, 2025

Events:

Quarterly Results

Announcement Date

Nov 14, 2025

Annual Report

Announcement Date

Sep 06, 2025

More Nano Cap Ideas

See similar 'Nano' cap companies with recent activity

Promoter Buying

Companies where the promoters are bullish

Detailed List

Capex

Companies investing on expansion

Detailed List

Superstar Investor

Companies where well known investors have invested

Detailed List

Popular questions

Business
Financials
Share Price
Shareholdings

What does Asston Pharma do?

Asston Pharmaceuticals is engaged in the manufacturing and export of both pharmaceutical formulations and nutraceutical products in domestic and various African markets. The company operates under brand ‘Asston’. The company is involved in the business of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel and Lotion) and Oral Powder (Sachet, Dry Syrup) etc.

Who are the competitors of Asston Pharma?

Asston Pharma major competitors are Shelter Pharma, Bafna Pharma, Trident Lifeline. Market Cap of Asston Pharma is ₹60 Crs. While the median market cap of its peers are ₹293 Crs.

Is Asston Pharma financially stable compared to its competitors?

Asston Pharma seems to be less financially stable compared to its competitors. Altman Z score of Asston Pharma is 0 and is ranked 4 out of its 4 competitors.

Does Asston Pharma pay decent dividends?

The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Asston Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

How has Asston Pharma allocated its funds?

Companies resources are allocated to majorly unproductive assets like Accounts Receivable

How strong is Asston Pharma balance sheet?

Asston Pharma balance sheet is weak and might have solvency issues

Is the profitablity of Asston Pharma improving?

The profit is oscillating. The profit of Asston Pharma is ₹1.94 Crs for TTM, ₹4.33 Crs for Mar 2025 and ₹1.36 Crs for Mar 2024.

Is the debt of Asston Pharma increasing or decreasing?

The net debt of Asston Pharma is decreasing. Latest net debt of Asston Pharma is ₹3.81 Crs as of Sep-25. This is less than Mar-25 when it was ₹6.86 Crs.

Is Asston Pharma stock expensive?

Asston Pharma is not expensive. Latest PE of Asston Pharma is 13.42, while 3 year average PE is 18.13. Also latest EV/EBITDA of Asston Pharma is 14.47 while 3yr average is 17.48.

Has the share price of Asston Pharma grown faster than its competition?

There is not enough historical data for the companies share price.

Is the promoter bullish about Asston Pharma?

Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Asston Pharma is 50.66% and last quarter promoter holding is 50.66%.

Are mutual funds buying/selling Asston Pharma?

There is Insufficient data to gauge this.

APL

Share Price

Financials

Summary

Profit & Loss

Balance sheet

Cashflow

Revenue mix

Product wise

Location wise

Shareholdings

Peers

Forensics

Recent events

News

Corporate Actions

Asston Pharmaceuticals' Unit 2 Commences Commercial Production

Asston Pharmaceuticals Receives Purchase Order

Events:

Quarterly Results

More Nano Cap Ideas

Promoter Buying

Capex

Superstar Investor

Popular questions

Business

Financials

Share Price

Shareholdings

What does Asston Pharma do?

Who are the competitors of Asston Pharma?

Is Asston Pharma financially stable compared to its competitors?

Does Asston Pharma pay decent dividends?

How has Asston Pharma allocated its funds?

How strong is Asston Pharma balance sheet?

Is the profitablity of Asston Pharma improving?

Is the debt of Asston Pharma increasing or decreasing?

Is Asston Pharma stock expensive?

Has the share price of Asston Pharma grown faster than its competition?

Is the promoter bullish about Asston Pharma?

Are mutual funds buying/selling Asston Pharma?